VAGELIS RINOTAS

Dr. VAGELIS RINOTAS

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in EMBO Reports
Verified
Journal Article
Closed access
AMArne Martens
Arne Martens
PHPieter Hertens
Pieter Hertens
DPDario Priem
Dario Priem
VRVAGELIS RINOTAS
VAGELIS RINOTAS
TMTheodore Meletakos
Theodore Meletakos
GLGeert van Loo
Geert van Loo

10 December 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
ALAlba Llop-Guevara
Alba Llop-Guevara
MPMónica Porras
Mónica Porras
CCCarla Cendón
Carla Cendón
ICIrene Di Ceglie
Irene Di Ceglie
FSFrancesco Siracusa
Francesco Siracusa
JRJuan Román
Juan Román
Despite the broad spectrum of antirheumatic drugs, RA is still not well controlled in up to 30-50 % of patients. Inhibition of JAK kinases by means of the pan-JAK inhibitor tofacitinib has demonstrated to be effective even in difficult-to-treat patients. Here, we discuss whether the efficacy of JAK inhibition can be improved by simultaneously inhibiting SYK kinase, since both kinases mediate complementary and non-redundant pathways in RA. Efficacy of dual JAK + SYK inhibition with selective small molecule inhibitors was evaluated in chronic G6PI-induced arthritis, a non-self-remitting and destructive arthritis model in mice. Clinical and histopathological scores, as well as cytokine and anti-G6PI antibody production were assessed in both preventive and curative protocols. Potential immunotoxicity was also evaluated in G6PI-induced arthritis and in a 28-day TDAR model, by analysing the effects of JAK + SYK inhibition on hematological parameters, lymphoid organs, leukocyte subsets and cell function. Simultaneous JAK + SYK inhibition completely prevented mice from developing arthritis. This therapeutic strategy was also very effective in ameliorating already established arthritis. Dual kinase inhibition immediately resulted in greatly decreased clinical and histopathological scores and led to disease remission in over 70 % of the animals. In contrast, single JAK inhibition and anti-TNF therapy (etanercept) were able to stop disease progression but not to revert it. Dual kinase inhibition decreased Treg and NK cell counts to the same extent as single JAK inhibition but overall cytotoxicity remained intact. Interestingly, treatment discontinuation rapidly reversed such immune cell reduction without compromising clinical efficacy, suggesting long-lasting curative effects. Dual kinase inhibition reduced the Th1/Th17 cytokine cascade and the differentiation and function of joint cells, in particular osteoclasts and fibroblast-like synoviocytes. Concurrent JAK + SYK inhibition resulted in higher efficacy than single kinase inhibition and TNF blockade in a chronic and severe arthritis model. Thus, blockade of multiple immune signals with dual JAK + SYK inhibition represents a reasonable therapeutic strategy for RA, in particular in patients with inadequate responses to current treatments. Our data supports the multiplicity of events underlying this heterogeneous and complex disease.

21 September 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VRVAGELIS RINOTAS
VAGELIS RINOTAS
Athanasios PapakyriakouAthanasios Papakyriakou
Athanasios Papakyriakou
FVFoteini Violitzi
Foteini Violitzi
CPChristos Papaneophytou
Christos Papaneophytou
MOMaria-Dimitra Ouzouni
Maria-Dimitra Ouzouni
Eleni K. DouniEleni K. Douni
Eleni K. Douni

9 August 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
VRVAGELIS RINOTAS
VAGELIS RINOTAS
KIKalliopi Iliaki
Kalliopi Iliaki
LPLydia Pavlidi
Lydia Pavlidi
TMTheodore Meletakos
Theodore Meletakos
GMGeorge Mosialos
George Mosialos
MAMaria ARMAKA
Maria ARMAKA
TNF is a potent cytokine known for its involvement in physiology and pathology. In Rheumatoid Arthritis (RA), persistent TNF signals cause aberrant activation of synovial fibroblasts (SFs), the resident cells crucially involved in the inflammatory and destructive responses of the affected synovial membrane. However, the molecular switches that control the pathogenic activation of SFs remain poorly defined. Cyld is a major component of deubiquitination (DUB) machinery regulating the signaling responses towards survival/inflammation and programmed necrosis that induced by cytokines, growth factors and microbial products. Herein, we follow functional genetic approaches to understand how Cyld affects arthritogenic TNF signaling in SFs. We demonstrate that in spontaneous and induced RA models, SF-Cyld DUB deficiency deteriorates arthritic phenotypes due to increased levels of chemokines, adhesion receptors and bone-degrading enzymes generated by mutant SFs. Mechanistically, Cyld serves to restrict the TNF-induced hyperactivation of SFs by limiting Tak1-mediated signaling, and, therefore, leading to supervised NF-κB and JNK activity. However, Cyld is not critically involved in the regulation of TNF-induced death of SFs. Our results identify SF-Cyld as a regulator of TNF-mediated arthritis and inform the signaling landscape underpinning the SF responses.

Verified
Journal Article
Open access
PDF file
VRVAGELIS RINOTAS
VAGELIS RINOTAS
FLFotini Liepouri
Fotini Liepouri
MOMaria-Dimitra Ouzouni
Maria-Dimitra Ouzouni
NCNiki Chalkidi
Niki Chalkidi
Christos PapaneophytouChristos Papaneophytou
Christos Papaneophytou
Eleni K. DouniEleni K. Douni
Eleni K. Douni
Receptor activator of nuclear factor-κB ligand (RANKL) has been actively pursued as a therapeutic target for osteoporosis, given that RANKL is the master mediator of bone resorption as it promotes osteoclast differentiation, activity and survival. We employed a structure-based virtual screening approach comprising two stages of experimental evaluation and identified 11 commercially available compounds that displayed dose-dependent inhibition of osteoclastogenesis. Their inhibitory effects were quantified through TRAP activity at the low micromolar range (IC50 < 5 μΜ), but more importantly, 3 compounds displayed very low toxicity (LC50 > 100 μΜ). We also assessed the potential of an N-(1-aryl-1H-indol-5-yl)aryl-sulfonamide scaffold that was based on the structure of a hit compound, through synthesis of 30 derivatives. Their evaluation revealed 4 additional hits that inhibited osteoclastogenesis at low micromolar concentrations; however, cellular toxicity concerns preclude their further development. Taken together with the structure–activity relationships provided by the hit compounds, our study revealed potent inhibitors of RANKL-induced osteoclastogenesis of high therapeutic index, which bear diverse scaffolds that can be employed in hit-to-lead optimization for the development of therapeutics against osteolytic diseases.

5 January 2022 in Journal of Proteome Research
Verified
Journal Article
Closed access
VPVasiliki-Iris Perivolidi
Vasiliki-Iris Perivolidi
FVFoteini Violitzi
Foteini Violitzi
EIElisavet Ioannidou
Elisavet Ioannidou
VRVAGELIS RINOTAS
VAGELIS RINOTAS
GSGeorge Stamatakis
George Stamatakis
Eleni K. DouniEleni K. Douni
Eleni K. Douni